| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2016 | 2015 | 2014 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 110,0 k € | -78.6% | 514,4 k € | -53.7% | 1,1 M € | -18.7% | 1,4 M € | +6.6% | 1,3 M € | +6.8% | 1,2 M € | +10.2% | 1,1 M € | +11.1% | 980,1 k € | +176.0% | 355,1 k € | -40.7% | 598,9 k € | +72.2% | 347,8 k € | +180.8% | 123,9 k € | |
| EBITDA | 70,2 k € | -86.2% | 507,5 k € | -13.1% | 583,8 k € | -38.6% | 951,1 k € | +41.8% | 670,8 k € | +21.7% | 551,1 k € | +2.3% | 538,5 k € | +10.7% | 486,4 k € | +251.7% | 138,3 k € | -24.4% | 183,0 k € | +251.3% | 52,1 k € | +151.6% | -101,0 k € | |
| Operating profit | 68,4 k € | -86.0% | 487,5 k € | -15.3% | 575,5 k € | -39.5% | 951,1 k € | +62.9% | 584,0 k € | +27.2% | 459,3 k € | +5.8% | 434,0 k € | +15.2% | 376,7 k € | +362.0% | 81,5 k € | +39.3% | 58,5 k € | +37.5% | 42,6 k € | +139.6% | -107,4 k € | |
| Profit/loss | -182,3 k € | -190.8% | 200,7 k € | -37.3% | 320,2 k € | -53.4% | 686,9 k € | +103.0% | 338,4 k € | +30.3% | 259,7 k € | +0.4% | 258,6 k € | +28.0% | 202,1 k € | +472.2% | 35,3 k € | +233.6% | 10,6 k € | -34.2% | 16,1 k € | +114.6% | -110,3 k € | |
| Equity | 1,9 M € | -8.8% | 2,1 M € | +10.8% | 1,9 M € | +20.8% | 1,5 M € | +48.8% | 1,0 M € | +48.6% | 697,0 k € | +59.4% | 437,3 k € | +144.7% | 178,7 k € | +864.7% | -23,4 k € | +60.2% | -58,7 k € | +15.3% | -69,3 k € | +18.9% | -85,4 k € | |
| Total assets | 7,6 M € | +0.1% | 7,6 M € | -10.3% | 8,5 M € | +320.4% | 2,0 M € | -28.7% | 2,8 M € | +22.6% | 2,3 M € | +3.4% | 2,2 M € | -17.8% | 2,7 M € | +44.3% | 1,9 M € | +4.8% | 1,8 M € | +550.9% | 276,5 k € | +85.4% | 149,1 k € | |
| Cash | — | — | 1,1 M € | -10.1% | 1,2 M € | +61.3% | 749,2 k € | +416.5% | 145,0 k € | +2.6% | 141,4 k € | -54.7% | 312,4 k € | +111.0% | 148,1 k € | +123.7% | 66,2 k € | +283.9% | 17,2 k € | — | ||||
| Debts | 5,5 M € | +3.6% | 5,3 M € | -19.4% | 6,6 M € | +1264.3% | 483,7 k € | -73.2% | 1,8 M € | +11.5% | 1,6 M € | -10.2% | 1,8 M € | -29.2% | 2,5 M € | +33.2% | 1,9 M € | +8.2% | 1,8 M € | +410.7% | 345,8 k € | +47.5% | 234,5 k € | |
| Staff | — | — | 4,7 | 6,9 | 10,3 | 11,3 | 9,9 | 10,7 | 10,5 | 8,3 | 7,4 | 4 | ||||||||||||
Private limited company · Gent · incorporated on 16/10/2012
Private limited company loss-making in the latest fiscal year. Cash position declining (-10.1%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
CREDOPHAR is a Private limited company incorporated in 2012. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Gent.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette